Abstract
Many tumor immunologists favor the hypothesis that optimal anti-tumor activity is mediated by type 1 CD4+ and CD8+ T cells, and that the production of type 2 CD4+ T cells may be counterproductive for effective anti-tumor immunity. Since Stat6-deficient or “knockout” mice lack the signal transducer and activator of transcription-6 protein and are unable to transmit signals initiated by the type 2 cytokines, IL-4 and IL-13, they have been studied to confirm the T h 1 vs T h 2 paradigm. Using transplantable tumor cells that cause primary solid tumors and metastatic disease, as well as a spontaneous transgenic tumor model, multiple studies have demonstrated that Stat6-/- mice are able to reject or delay primary tumor growth, prevent recurrence of primary tumors, and/or reject established, spontaneous metastatic disease. Deletion of the Stat6 gene, therefore, provides significantly enhanced immunosurveillance. Comparable experiments with CD1-deficient mice, which lack NKT cells and hence are deficient for IL-13, give similar results and suggest that removal of NKT cells also enhances immunosurveillance. Because immunity is enhanced in the absence of Stat6 or CD1, it has been hypothesized that these deletions result in the removal of an inhibitor that blocks constitutive immunosurveillance. Several mechanisms have been tested as potential inhibitors, including CD4+CD25+ T regulatory cells, IL-13, a T h 2 shift, and myeloid suppressor cells. Although the first three mechanisms do not appear to be relevant, regression of myeloid suppressor cells in Stat6-deficient and CD1-deficient mice may be responsible for enhanced immunosurveillance. Although additional studies are clearly needed to clarify the mechanism(s) underlying improved anti-tumor immunity in Stat6-/- and CD1-/- mice, deletion of these genes results in a potent anti-tumor immunity and may be a basis for an immunotherapy strategy.
Similar content being viewed by others
Abbreviations
- Stat6:
-
signal transducer and activator of transcription 6
- MSC:
-
myeloid suppressor cell
- BALB/c NeuT:
-
transgenic mice that spontaneously develop mammary carcinoma
- Stat6-/-NeuT+/- :
-
Stat6-deficient, BALB/c NeuT mice
- Stat6-/-IFNγ-/- :
-
Stat6-deficient, interferon-γ-deficient BALB/c mice
References
Aslakson C, Miller F (1992) Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52:1399
Bellone G, Turletti A, Artusio E, Mareschi K, Carbone A, Tibaudi D, Robecchi A, Emanuelli G, Rodeck U (1999) Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol 155:537
Boggio K, Nicoletti G, Di Carlo E, Cavallo F, Landuzzi L, Melani C, Giovarelli M, Rossi I, Nanni P, De Giovanni C, Bouchard P, Wolf S, Modesti A, Musiani P, Lollini PL, Colombo MP, Forni G (1998) Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med 188:589
Bronte V, Serafini P, Apolloni E, Zanovello P (2001) Tumor-induced immune dysfunctions caused by myeloid suppressor cells. J Immunother 24:431
Constant S, Bottomly K (1997) Induction of the TH1 and TH2 CD4+ T cell responses: alternative approaches. Annu Rev Immunol 15:297
Dobrzanski MJ, Reome JB, Dutton RW (1999) Therapeutic effects of tumor-reactive type 1 and type 2 CD8+ T cell subpopulations in established pulmonary metastases. J Immunol 162:6671
Dobrzanski MJ, Reome JB, Dutton RW (2001) Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection. J Immunol 167:424
Gajewski TF, Fallarino F, Uyttenhove C, Boon T (1996) Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7–1 over B7–2 for active tumor immunization. J Immunol 156:2909
Heim M (1999) The Jak-STAT pathway: cytokine signalling from the receptor to the nucleus. J Recept Signal Transduct Res 19:75
Hu HM, Urba WJ, Fox BA (1998) Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile. J Immunol 161:3033
Ihle J, Nosaka T, Thierfelder W, Quelle F, Shimoda K (1997) Jaks and Stats in cytokine signaling. Stem Cells [Supp 1]:105
Jensen SM, Meijer SL, Kurt RA, Urba WJ, Hu HM, Fox BA (2003) Regression of a mammary adenocarcinoma in STAT6-/- mice is dependent on the presence of STAT6-reactive T cells. J Immunol 170:2014
Joyce S, Van Kaer L (2003) CD1-restricted antigen presentation: an oily matter. Curr Opin Immunol 15:95
Kacha AK, Fallarino F, Markiewicz MA, Gajewski TF (2000) Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice. J Immunol 165:6024
Kaplan M, Grusby M (1998) Regulation of T helper cell differentiation by STAT molecules. J Leukoc Biol 64:2
Kobayashi M, Kobayashi H, Pollard RB, Suzuki F (1998) A pathogenic role of Th2 cells and their cytokine products on the pulmonary metastasis of murine B16 melanoma. J Immunol 160:5869
Liu K, Gaffen S, Goldsmith M (1998) JAK/STAT signaling by cytokine receptors. Curr Opin Immunol 10:271
Lucchini F, Sacco MG, Hu N, Villa A, Brown J, Cesano L, Mangiarini L, Rindi G, Kindl S, Sessa F et al (1992) Early and multifocal tumors in breast, salivary, harderian and epididymal tissues developed in MMTY-Neu transgenic mice. Cancer Lett 64:203
Matsui S, Ahlers JD, Vortmeyer AO, Terabe M, Tsukui T, Carbone DP, Liotta LA, Berzofsky JA (1999) A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL. J Immunol 163:184
Mattes J, Hulett M, Xie W, Hogan S, Rothenberg ME, Foster P, Parish C (2003) Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process. J Exp Med 197:387
Miller F, Miller B, Heppner G (1983) Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. Invasion Metastasis 3:22
Murata T, Obiri NI, Puri RK (1998) Structure of and signal transduction through interleukin-4 and interleukin-13 receptors (review). Int J Mol Med 1:551
North RJ, Digiacom A, Dye E (1987) Suppression of antitumor immunity. In: Den Otter W, Ruitenberg EJ (eds) Tumor immunology: mechanisms, diagnosis, therapy. Elsevier, Amsterdam, p 125
Ostrand-Rosenberg S, Grusby MJ, Clements VK (2000) Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma. J Immunol 165:6015
Ostrand-Rosenberg S, Clements VK, Terabe M, Park JM, Berzofsky JA, Dissanayake SK (2002) Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-gamma dependent. J Immunol 169:5796
Piccirillo CA, Shevach EM (2001) Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 167:1137
Pulaski B, Ostrand-Rosenberg S (1998) MHC class II and B7.1 immunotherapeutic cell-based vaccine reduces spontaneous mammary carcinoma metastases without affecting primary tumor growth. Cancer Res 58:1486
Pulaski B, Ostrand-Rosenberg S (2000) Mouse 4T1 breast tumor model. In: Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W (eds) Current protocols in immunology. Wiley, New York, p 20.2.1
Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25): breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155:1151
Salvadori S, Martinelli G, Zier K (2000) Resection of solid tumors reverses T cell defects and restores protective immunity. J Immunol 164:2214
Serafini P, De Santo C, Marigo I, Cingarlini S, Dolcetti L, Gallina G, Zanovello P, Bronte V (2003) Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother (in press)
Shevach EM (2002) CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2:389
Shimoda K, van Deursen J, Sangster M, Sarawar S, Carson R, Tripp R, Chu C, Quelle F, Nosaka T, Vagnali D, Doherty P, Grosveld G, Paul W, Ihle J (1996) Lack of IL-4-induced Th2 response and IgE class switching in mice with distrupted STAT6 gene. Nature 380:630
Shurin M, Lu L, Kalinski P, Stewart-Akers A, Lotze M (1999) Th1/Th2 balance in cancer, transplantation and pregnancy. Springer Semin Immunopathol 21:339
Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R, Melief CJ (2001) Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194:823
Terabe M, Matsui S, Noben-Trauth N, Chen H, Watson C, Donaldson DD, Carbone DP, Paul WE, Berzofsky JA (2000) NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 1:515
Acknowledgements
The authors thank Dr Guido Forni for generously providing breeding pairs of the BALB/c NeuT mice used in these studies. We also thank Dr Beth Pulaski for setting up the BALB/c NeuT × Stat6-/- matings, and Ms Sandy Mason for her capable care of the mice.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article forms part of the Symposium in Writing “Inhibitors of immunosurveillance and anti-tumor immunity,” published in Vol. 53. These studies were supported by NIH R01CA52527 and R01CA84232, and by DOD US Army Research and Materiel Command DAMD17-01-1-0312. Reported animal studies adhered to NIH guidelines for the humane treatment of laboratory animals, and have been approved by the UMBC IACUC.
Rights and permissions
About this article
Cite this article
Ostrand-Rosenberg, S., Sinha, P., Clements, V. et al. Signal transducer and activator of transcription 6 (Stat6) and CD1: inhibitors of immunosurveillance against primary tumors and metastatic disease. Cancer Immunol Immunother 53, 86–91 (2004). https://doi.org/10.1007/s00262-003-0446-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-003-0446-z